Table 3 List of adverse events of any grade.

From: Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals

Adverse event

Any grade

Grade 1

Grade 2

Grade 3

Grade 4

Asthenia

76 (74%)

61 (60%)

15 (15%)

-

-

Increased alanine aminotransferase level

66 (65%)

59 (58%)

7 (7%)

-

-

Increased aspartate aminotransferase level

56 (55%)

54 (53%)

2 (2%)

-

-

Peripheral neuropathy

42 (41%)

20 (20%)

16 (16%)

6 (6%)

-

Nausea

41 (40%)

39 (38%)

2 (2%)

-

-

Arthralgia

35 (34%)

29 (28%)

4 (4%)

2 (2%)

-

Myalgia

33 (32%)

28 (27%)

3 (3%)

2 (2%)

-

Thrombopenia

33 (32%)

28 (27%)

5 (5%)

-

-

Neutropenia

30 (30%)

10 (10%)

18 (18%)

2 (2%)

-

Headache

28 (27%)

26 (25%)

2 (2%)

-

-

Epistaxis

26 (26%)

25 (25%)

1 (1%)

-

-

Constipation

25 (25%)

22 (22%)

3 (3%)

-

-

Cutaneous and mucosal dryness

20 (20%)

20 (20%)

-

-

-

Anemia

20 (20%)

18 (18%)

2 (2%)

-

-

Epigastralgia

18 (18%)

18 (18%)

-

-

-

Diarrhea

13 (13%)

11 (11%)

2 (2%)

-

-

Mucitis

12 (12%)

11 (11%)

1 (1%)

-

-

Dysgeusia

8 (8%)

8 (8%)

-

-

-

Gingivorrhagia

6 (6%)

5 (5%)

1 (1%)

-

-

Abdominal pain

3 (3%)

3 (3%)

-

-

-

Hyperbilirubinemia

3 (3%)

3 (3%)

-

-

-

Decreased Left Ventricular Ejection Fraction

2 (2%)

-

2 (2%)

-

-

Rhinitis

2 (2%)

2 (2%)

-

-

-

Infusion Related Reaction

2 (2%)

1 (1%)

1 (1%)

-

-

Pneumopathy

1 (1%)

-

1 (1%)

-

-

  1. Boxes with a “-” sign indicate no event (N = 0, 0%).